Suisse Life Science Group is a digital biological intelligence group proudly rooted in Switzerland and headquartered in London.

Obsessively focused on developing smart, “personalization” technologies, that seamlessly integrated into the user’s lifestyle, Suisse Life Science has created the world’s first remote Lifestyle Medicine system based on consumer mobile devices to maximize human potential by managing a healthy life proactively, through contextualized, science-based advice and drug-free customized age management products.


My iDDNA® is the only technology that automatically customizes lifestyle interventions – in real time – based on the user’s profile, references and contextual detection of

  • Pollution
  • UV exposure
  • Humidity
  • Temperature
  • Stress level
  • Sleep quality time
  • Blood pressure
  • Heart rate
  • Fitness level
  • Food logging
  • Water intake
  • Lifestyle activity logging
  • Body temperature.


The world is moving from a disease-centric to a preventive approach to healthcare. With advancements in healthcare from genetics to nutrition, people are becoming more aware of their well-being and lifestyle as a whole, which is a key factor for disease prevention, human performance and healthy aging.

Consumers have an abundant, sometimes overwhelming choice of products and services aimed at improving their well-being. Self-care and healthy aging in particular is taken seriously by an increasing number of people. But there is a crucial issue with the existing ecosystem: marketing pressure forces consumers towards the choices of manufacturers; marketing creates trends; and while often backed by research, the overlap of offers and contradictory messages is confusing to a consumer that is becoming savvy, informed and sophisticated.

Personalization is a clear trend, with evident benefits from a scientific standpoint that aid consumer adoption.


World population is set to increase to nearly 10bn people in 2050, with the age pyramid drastically changing as an increasing number of people will be over 30.

Lifespan has more than doubled since 1900, and life expectancy currently exceeds 71 years according to WHO. People look more towards extending good health and engaging in various wellness activities.

Because the population is rapidly growing and aging, the global market for anti-aging products, technologies and services is forecast to grow from $282 billion in 2015 to $331 billion in 2020 as projected by the Global Wellness Institute.


Less than three decades ago, wellness was about solving baseline health and wellness conditions (disease-centric). Now people are redefining food culture, exercising and wellness as a whole (health-centric).

The wellness market has grown at an average of more than 11% p.a., from $1.9 trillion in 2009 to more than $3.7 trillion in 2015.

People are more concerned with healthy living and aging, which drives demand for various related products:

  • Nielson’s Global Health and Wellness Report reveals that 50% of people are trying to lose weight, with 72% doing physical exercise and 75% changing their diet.
  • One of the most popular wellness data-driven solutions – fitness trackers – is set to triple between 2014 and 2019 to a more than $5bn global market.


Developing technology has also allowed for multi-disciplinary scientific age management to emerge. While medicine and life science are still radically separated by specialty, scientific age management approaches the problem across disciplines.

As people begin to take self-care more seriously, market opportunities are created and new wellness sources emerge – superfoods, bio ingredients, nutrition products, high-end cosmetics, exercise methods, “magical” diets and an increasing number of data-driven solutions such as fitness trackers.


Sophisticated customers follow the organic (bio), holistic trend and accept aging as a natural process. This demographic embraces/co-designs a cultural shift towards natural aging. They are informed, high-spending customers who desire to preserve their unique look and feel while aging. They take a progressive, active approach to aging and embrace the latest innovations with a critical approach if they are drug-free.

These are healthy customers, technology-savvy, with a clear understanding of age management, who see a preventative approach as a whole and not as single products. They have a clear perception of lifestyle as a key factor in age management.


According to Global Data, various wellness-related industries now have more cross-over between them. More consumers are aware of how nutrition affects their health and physical appearance, with 56% of consumers concerned about the impact of their diet on health and appearance.


However, most of the existing and emerging tools that are being used are “one-size-fit-all” and despite some of them generating huge amounts of data, personalization remains limited. Bain & Сompany found in a survey that in New York, Munich and New Delhi, 61% of people want to be able to make more personalized choices to stay healthy; 65% agreed that information should be simple, scientific, integrated and personalized.

To adopt a solution that is somewhat tailored to one’s body and lifestyle, there is a need for the professional help of external providers, such as specialized clinics – a timely and expensive process. Most personalization efforts are still limited to personalized medicine, mainly focused on cancer cures.


Technology has also enabled the growth of the digital health market, which is projected to grow to more than $230bn by 2020. Mobile health, or mHealth, is forecast to increase almost 10-fold, to $102bn in 2022 from $11bn in 2014.


The wearables market has grown immensely over the last decade, but it’s fighting to live up to the hype. Market leaders such as Fitbit and Jawbone are struggling, and data is emerging that wearables could actually be counterproductive when it comes to losing weight. However, there appears to be a bright future for wearables in the healthcare segment.

Platforms that utilize and convert the data generated by wearables into useful, actionable information could prove to be the niche where companies can find growth. But although the technology and customer demand exist, there is no single, user-friendly platform that provides customers with actionable, data-driven recommendations and products that are uniquely personalized.

Suisse Life Science Group has built a platform focused on age-management that uses various sources of data and converts them into actionable plans for healthy anti-aging.


To deepen engagement, anti-aging providers increasingly turn to automated technology that gives patients access to self-care, regardless of location or health status – enabling providers to care for more patients, more efficiently and more economically. With built-in intelligence, the technology can send patients self-management recommendations or other educational content based on their responses to auto-detected data from devices (smartphones and wearables) and self-reported data from interactive survey questions. This creates a seamless, continuous conversation between patient and provider that engages the patient, informs the provider, and leads to better health management overall.


Every two years the world’s database doubles, and every three years health information alone also doubles. By 2020, global healthcare data will double every three days – with 80% of the data being unstructured, without a clear relationship. To truly get the results consumers deserve, health and wellness data need to translate into accurate, actionable recommendations for both consumers and professionals.


As patients assume more financial responsibility for sharing the cost of the healthcare services they use, they want to have more control over their experience with providers and insurers. They seek the same high level of service other industries offer, demanding rapid responsiveness to whatever they need, and expecting an easy-to-understand electronic interaction with their service provider. Remote continual care technology accelerates their move from passive patients to proactive, empowered consumers.


According to life science visionary John Nosta, Google and Apple are the next big pharma:

“I wonder if the innovations of Google and Apple are another wake-up call for the life science industry which oftentimes has relied on the snooze function of line extensions and extended-release drugs as the source of income and innovation.”

We’re beyond the days when we’re shocked that a life science innovation doesn’t come from Big Pharma. Yet interestingly, when a Google or Amazon or Apple enters the market with a “significant” innovation, the reaction is more a nod in acknowledgment than a significant surprise. In dramatic contrast to these tech innovations, we find the pharma “big news” headlines are more along the lines of soaring drug costs and executive behavior.

Today’s model of innovation is a far cry from the “molasses hierarchy” of only a few short years ago. And it’s important to point out that much of pharma must be credited for significant advances, including areas like genomics and oncology. And everyone seems to have their accelerator or center of excellence. Yet, in my experience, they are sometimes more a senior management imperative or a check in the box than something that actually moves fast or is focused on excellence.


The healthcare industry is not what it used to be. Changes have been gradual, but fundamental. The industry is facing challenges like price reductions, declining profits, regulatory pressures and extend as far as weak patent protection laws. These pressures force pharmaceutical companies to widen their customer base without overstepping boundaries. Furthermore, hospital authorities impose restrictions on medical representatives, limiting face time with Healthcare Practitioners (HCP).

On top of this, there has been a declining appetite among healthcare providers for attending promotional or educational programs organized by pharmaceutical companies – because of a mix of the above reasons, in addition to alternate sources of reliable information thanks to the internet.

In the face of this challenge, the industry is casting a hopeful eye towards the digital world.

Digital Spend Across Industries - 2014
Retail $11.1B
Financial Services $6.2B
Automotive $6.2B
Telecommunications $5.6B
CPG $4.2B
Travel $4.2$
Consumer Electronics $3.8B
Media $2.8B
Entertainment $2.4B
Healthcare and Pharma $1.4B
Source: Deloitte


Customizing content for continual, proactive health and wellness

It’s a process of ongoing education, customized pathways, and continual care. First, the patient is introduced to the services available through remote care. Then, when the patient begins to use these tools, providers can automatically tailor pathways to patient needs. With customized content and daily interaction, the patient develops a steady relationship with the provider. The net effect is continuous engagement and greater care efficiency at a much lower cost. Eventually, we move from providing episodic care to delivering truly continual care, with the hands-on care experience reserved for when it’s truly needed.

Curtailing costs and driving revenue
Collecting evidence that it works
Caring for the healthy

If you’re a patient visiting a specific provider organization, whether a physician’s office or a hospital, we want you to walk out with a solution on your phone or tablet that brings you continual care. We want every health care consumer – not only high-risk patients with multiple chronic illnesses but also those who are healthy – to have an ongoing relationship with their provider. Then, when they experience a change in their health status, the connected experience is already in place that will help them achieve the best possible outcomes through continuous provider oversight.

Catalyzing the provider-patient relationship

The increased use of these technologies doesn’t mean hospitals and physician offices are going away. Providers still deliver the initial episode of care that patients trust. Digital health tools serve as relationship extenders, bringing the interaction from the provider setting into the home – or wherever the patient happens to be.


Suisse Life Science Group’s IP includes:

  • Proprietary genetic panels, methods, and life science knowledge base
  • Patent-pending proprietary
    bioinformatics algorithms
  • Trademarks and patents.

For example, the following Swiss patent filings:

  • Methods for generating and screening metabolic and genetic diversity in order to prevent aging-related diseases
  • Bioinformatics data mining platform for targeted knowledge discovery and precision medicine
  • Metabolic matching-diet and dynamic food environment reorganization for active weight management and disease prevention
  • Methods for identifying a subject’s macronutrient sensitivity
  • Methods for identifying a subject’s micronutrient sensitivity
  • Multi-tier approach and integrated genomic services to prevent celiac disease and genetic food sensitivities
  • Methods and algorithms to generate and adapt in real-time a healthy weight management plan (macronutrient ratio, micronutrient needs, preventive nutrition, metabolic exercise needs, epigenetic chrono-nutrition) to fit the subject’s biological age and lifestyle.


Suisse Life Science manages its services on a proprietary custom genotyping panel designed on the Affymetrix Precision Medicine v2 DTC Axiom Array.

Suisse Life Science’s genetic panel is currently the broadest lifestyle genetic panel in the world, and the most comprehensive array focused only on qualitative interpretation of the root causes of aging.

The Affymetrix Precision Medicine (PM) array technology platform incorporates multiple content categories. This includes a genome-wide association study (GWAS) panel of markers for genome-wide coverage in major ethnic groups, rare coding SNPs and indels for exome analysis, pharmacogenomics markers, eQTLs, and newly discovered loss-of-function variants, which include sequence insertions and deletions from recent exome sequencing initiatives, totaling ~820,000/975,000 SNPs (Affymetrix is now part of Thermo Fisher Scientific Inc. {NYSE: TMO}, the world leader in serving science, with revenues of $17bn and more than 50,000 employees in 50 countries).

Suisse Life Science’s custom chip was designed by our R&D to include:

  • About 2,800 SNPs (human biomarkers on the array on at least one strand (both where possible), tiled at 4 replicates (per strand)
  • 175 VNTR human markers.

Those genetic markers are individually interpreted, generating a personal Genetic Positioning System (GPS) map, according to

  • Genetic and metabolic published cross-references
  • Individual lifestyle and goals
  • Real-time detected lifestyle and environmental conditions.

This GPS goes above and beyond any existing age management approach, creating a real-time, dynamic map between your genetic predispositions and risks (DNA-connections) and genetic and metabolic associations with nutrients, metabolites, environment and lifestyle.

Your GPS represents your body ecosystem. Informed by your biomarkers and real-time data from your devices (mobile phone or wearable), my iDDNA® technology puts you in touch with your health and wellness, querying your GPS depending on your goals.

Suisse Life Science’s GPS methods are grounded in published metabolic associations and scientific aging theories.

To run on the GeneTitan the custom Affymetrix Precision Medicine v2 DTC (DTC) Axiom Array, DNA is extracted from the samples using the Thermo King-Fisher Flex DNA extraction instrument utilizing Qiagen chemistry.


invest in digital health
Partners S.p.A.

Suisse Life Science Group ShareholdersNationality

DeepMind Ventures Ltd.49.56%
GDTRE Srl17.30%
Gandini’s family10.78%
Bonsai Capital20.00%
Tamburi Investment Partners S.p.A.2.36%

DeepMind Ventures Ltd. is an investment company representing Suisse Life Science founder and top management.

Bonsai Capital Ltd. is a principal investor in early-stage Life Science companies, focused on startups developing medicines, platform technologies, and diagnostics.

GDTRE S.r.l. is a privately held Italian company and investor in the lifestyle, fashion, and food industries.

Tamburi Investment Partners S.p.A. is an independent Italian investment-merchant bank specializing in “excellent” small-to mid-sized companies (€1.2bn direct investments and club deals) – listed on FTSE MIB.

Suisse Life Science Group’s shareholders are completed by HNWI, prime investors in private equity.